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Carbohydrate based peptidomimetics
Dysfunction of integrin-mediated adhesion is often related to cancer metastasis, angiogenesis
and osteoporosis. The most biologically relevant αIIbβ3 and αVβ3 integrins recognise the short
Arg-Gly-Asp (RGD) peptidic sequence exhibited by their proteic ligands, fibronectin,
vitronectin and other proteins of the extracellular matrix. A major problem with inhibition of
adhesion is to achieve this with selectivity of a protein vis-à-vis of a particular integrin. This
selectivity is thought to be related to a bioactive conformation of the RGD sequence and could
be specific for its receptor. In the present work, the authors have designed novel selective
RGD mimics based on chiral scaffolds using a combination of computer aided design and a
solution phase combinatorial approach for compound synthesis (Design, synthesis and
preliminary biological evaluation of a focused combinatorial library of stereodiverse
carbohydrate-scaffold-based peptidomimetics, Y. Chapleur et. al., Bioorg. Med. Chem. Lett.,
9, (2001), 511-523).
A library of 126 mimetics of the RGD sequence based on the D-xylose sugar scaffold was
synthesised in solution in mixtures of 14. These mixtures were then tested by estimating the
adhesion of S180 sarcoma cells, which expresses only the αVβ3 integrin, on a substrate of
fibronectin or vitronectin in the presence of the compounds, and compared to the effect of the
RGDS peptide as reference on the same cells. Active mixtures identified were iteratively
deconvoluted followed by resynthesis of individual compounds to determine activity. One of
the most potent compounds discovered was (i) which gave a %inhibition of approximately
45% in this assay, identical to the RGDS peptide. This library has been successful in
identifying compounds with moderate activity as antagonists of the αVβ3 integrin and could be
useful in the future for the construction of other biological relevant libraries of
peptidomimetics, and in the design of synthetic receptors using parallel synthesis.
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Neuropeptide FF Antagonists
Opiate tolerance, dependence and abuse represent major medical and social problems.
Neuropeptide FF (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2), together with the related
mammalian neuropeptides NPAF and the N-terminally extended (Ser-Gln-Ala-) (ii) have been
identified as high affinity endogenous ligand for a novel neuropeptide Y-like human orphan G-
protein coupled receptor HLWAR77. Neuropeptide FF is an anti-opioid and has been
implicated in pain modulation, morphine tolerance and morphine abstinence. Antagonists of
(ii), besides their importance as pharmacological agents helpful in defining the physiological
and pharmacological role of the endogenous neuropeptide, may allow for the management of
withdrawal symptoms that adversely effect the treatment of opiate abuse. The present research
searches for novel antagonists of (ii) that show improved potency whilst retaining the ability to
cross the blood brain barrier (Combinatorial lead optimisation of a neuropeptide FF
antagonist, L. Prokai et. al., J. Med. Chem., 44, (2001), 1623-1626).
A library of 741 compounds was synthesised in mixtures of 19 on a Rink amide-
methoxybenzylhydrazine (MBHA) resin (AnaSpec Inc., San Jose, CA). Screening of these
mixtures in a rat spinal cord membrane preparation for displacement of [125I]YLFQPQRF-NH2
(iii) gave several active mixtures. Mixtures containing glycine (G), lysine (L) and glutamine
(Q) showed the highest increase in the percentage displacement of (iii) upon screening.
Following deconvolution of the active mixtures, one of the most active compounds obtained
was (iv) which gave a measured Ki value in the radioligand-binding assay of 1.4 +/- 0.5 µM.
This work has provided moderately potent antagonists of (ii) which are able to cross the blood
brain barrier and lays the foundation for the design of more potent inhibitors in the future.
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